CD274 and neoplasm: Despite the consensus that B16 melanomas are refractory to anti-PD-L1 monotherapy (10, 23), addition of anti-PD-L1 to the ADU-S100 treatment regimen yielded improved anti-tumor efficacy in this model (Figure 2B).